Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Tobias ElseEric JonaschOthon LliopoulosKathryn E BeckermannVivek NarayanBenjamin L MaughanStephane Marie OudardJodi K MaranchieAne B IversenCynthia Muller GoldbergWei FuRodolfo F PeriniYanfang LiuW Marston LinehanRamaprasad SrinivasanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Belzutifan continued to show robust activity and manageable safety in VHL disease-associated pNETs.
Keyphrases